Global pharmaceutical leader Eli Lilly and Company has announced a landmark ₹9,000 crore investment to set up a large-scale manufacturing and quality hub in Hyderabad, further strengthening India’s position in the global pharmaceutical value chain. The announcement followed a meeting between Lilly’s top leadership and Telangana Chief Minister Revanth Reddy, as confirmed by State IT Minister Sridhar Babu Duddilla.

The new facility will significantly expand Lilly’s global manufacturing and supply network, driving innovation and operational excellence. It is also expected to create thousands of high-value jobs across engineering, chemistry, analytics, and quality functions, reinforcing Telangana’s reputation as a hub for advanced life sciences and R&D capabilities.

Chief Minister Reddy stated, “Telangana is emerging as a preferred destination for global investors. This investment from Eli Lilly will further strengthen our vision of making the state a global leader in pharma innovation and opportunity.”

The move builds on Lilly’s recent establishment of a Global Capability Centre (GCC) in Hyderabad, underscoring the city’s growing strategic importance. Aligned with the Make in India vision, this initiative highlights Lilly’s commitment to developing breakthrough medicines for diabetes, obesity, Alzheimer’s, cancer, and autoimmune diseases.